Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study

被引:0
作者
Carlos Escobar
Cristóbal Morales
Margarita Capel
Susana Simón
Ferran Pérez-Alcántara
Elisenda Pomares
机构
[1] Hospital La Paz,Cardiology Department
[2] Hospital Vithas Sevilla,Endocrinology Department
[3] AstraZeneca,HEOR & Market Access
[4] Oblikue Consulting S.L.,undefined
来源
BMC Health Services Research | / 22卷
关键词
Cost-effectiveness analysis; Dapagliflozin; DECLARE; Type 2 diabetes mellitus; Spain;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 159 条
[1]  
Crespo C(2013)Direct cost of diabetes mellitus and its complications in Spain (SECCAID Study: Spain estimated cost Ciberdem-Cabimer in Diabetes) Avances en Diabetología 29 182-9
[2]  
Brosa M(2012)Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study Diabetologia 55 88-93
[3]  
Soria-Juan A(2020)Incidence of diabetes mellitus in Spain as results of the nation-wide cohort di@bet.es study Scientific Reports 10 2765-57
[4]  
Lopez-Alba A(2019)Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes New England Journal of Medicine 380 347-59
[5]  
López-Martínez N(2004)A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) Diabetologia 47 1747-33
[6]  
Soria B(2013)UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82 Diabetologia 56 1925-53
[7]  
Soriguer F(1998)Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) The Lancet 352 837-85
[8]  
Goday A(2013)Computer Modeling of Diabetes and Its Complications: A Report on the Fifth Mount Hood Challenge Meeting Value in Health 16 670-61
[9]  
Bosch-Comas A(2015)Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model Cost Effectiveness and Resource Allocation 13 12-9
[10]  
Bordiú E(2015)Refitting of the UKPDS 68 Risk Equations to Contemporary Routine Clinical Practice Data in the UK PharmacoEconomics 33 149-10